Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. - Wikidata - wikimedia - TriplyDB

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease.

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease.

http://www.wikidata.org/entity/Q35758533

about

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives Glomerular disease in patients with infectious processes developing antineutrophil cytoplasmic antibodies Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Updates in ANCA-associated vasculitis Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study Granulomatosis with polyangiitis (Wegener's) as a necrotizing gingivitis mimic: a case report.What Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis Population Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service.Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.Pituitary granulomatosis with polyangiitis Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease Is serum HMGB1 a biomarker in ANCA-associated vasculitis?Key advances in the clinical approach to ANCA-associated vasculitis.Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.Treatment of granulomatosis with polyangiitis (Wegener's).A retrospective study on the outcomes of MPO-ANCA-associated vasculitis in dialysis-dependent patients.Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn.Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity.Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients.Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population.Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.Glomerular disease: ANCA-associated GN--to PLEX or not to PLEX?Maintenance of clinical remission in ANCA-associated vasculitis.Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.The impact of intravenous methylprednisolone pulses on renal survival in anti-neutrophil cytoplasmic antibody associated vasculitis with severe renal injury patients: a retrospective study.Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

P2860

Q26776308-6BDF609C-CAE1-427C-A5E5-5548EA646A55 Q27021715-1D0CE588-9995-4C13-BBE1-9DB3291E4490 Q27025692-14501BD7-8ACE-4F84-BA29-B4758695A886 Q28069897-804AA342-D01E-4DF0-835F-9BA185477FB5 Q33767030-3CED7172-6589-43FD-A143-F45F463000ED Q34212522-6EE7613C-3DDC-4DB0-AFD6-E457BCC1B43F Q34971461-10D372C9-9893-4C7E-8A5F-37796F7F52C9 Q35065425-C2307709-780D-45A1-AD42-C0D2197DFD77 Q35836369-0D49BB28-420E-4AD5-B849-000F234F6799 Q36134791-9DA9DC49-F554-4BE3-A9D4-68845F673C3C Q36242872-7300D90D-7EFB-4F51-850A-1DD976BD3F16 Q36652819-828D2E7A-9322-46D1-ABC8-79FAD49868FD Q36893829-A43ADC37-4BF2-494E-BB3D-AA78E91ADBD6 Q37037298-3E6CF084-D5BC-4EE3-8401-95BBB17F5445 Q37690507-957CE140-91C9-4707-8D05-16CF496C2B73 Q38224803-16DCA4B4-1791-4539-B131-7541555EE548 Q38316279-BC990205-ACFE-44B5-B1B9-D2CD4B9416CA Q38341601-D2486558-8631-47F0-9541-127C070664B5 Q38475970-75181B8E-2561-4D89-A5F9-57B5E1CD077E Q38965278-CECFA1DA-DCD5-4DE7-83CC-D5B48FFBE291 Q39088103-2589C9A5-5096-4EC3-8B7B-9CD6AED4D1E1 Q40067987-DFA4E3A9-3969-4E82-BE1B-EA38866EF332 Q40570832-109C05F2-E5BD-433C-8E5B-B7EE7CABF5F3 Q40678626-CF49A7BB-7BB1-49D9-B651-5E781A8B7B63 Q40948863-8940B2B3-785A-4440-A35E-A33B138A2FC0 Q41428133-BEBC5288-E6CA-4CDF-BB72-46BC0AC5F615 Q44119588-0EE8ACF7-F9FD-4B9F-80FC-2D9D8E53DFFA Q45752892-370F01B9-5AFD-4955-91E4-DCC2449B090E Q46609151-FD4DC787-EFB0-402B-A439-95C2E10A2E33 Q47154902-506A3218-E899-4435-8A52-AFF5C80DB083 Q47619266-109140F4-504B-44ED-90F0-E4DD2E95F0F8 Q50076914-BE258561-1EB5-4431-B0BA-7739456F78F3

P2860

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease.

http://www.wikidata.org/entity/Q35758533

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Glucocorticoids and relapse an ...... cytoplasmic antibody disease.

@ast

Glucocorticoids and relapse an ...... cytoplasmic antibody disease.

@en

type

label

Glucocorticoids and relapse an ...... cytoplasmic antibody disease.

@ast

Glucocorticoids and relapse an ...... cytoplasmic antibody disease.

@en

prefLabel

Glucocorticoids and relapse an ...... cytoplasmic antibody disease.

@ast

Glucocorticoids and relapse an ...... cytoplasmic antibody disease.

@en

P1433

Q35758533-5C094C4B-A2BF-48D0-8938-CA757F76AFFA

P1476

Q35758533-0D65B7FD-3F81-4EE8-A231-43BAAD65852D

P2093

Q35758533-135D6664-82A0-4141-8539-DDE765DC5E5D

Q35758533-187D7E4B-86DC-4892-9E84-EE620BCE544E

Q35758533-1AD61A78-F325-4E69-9B84-53D4FF0127A5

Q35758533-722F79BE-B3DD-4B8D-B3E2-C0DE3F2A6D61

Q35758533-88D13C20-1C9A-4DBD-8483-8119DABA578D

Q35758533-D58DF18F-F5B6-4F14-988A-124C52B28B28

P2860

Q35758533-147147C7-DEB7-4EA9-B9E5-55E2A78918ED

Q35758533-1475483C-4AAA-46A6-9423-651C981239C7

Q35758533-181AF7C0-F718-4DCB-BA8B-7ED985A9F588

Q35758533-49FB1BB7-66B9-4BDF-A797-1263B65FB1C9

Q35758533-4FF4D47B-5FDB-482D-84B1-4ABA379A5215

Q35758533-5F80EC6A-151C-4C59-BB51-201D6C0880B5

Q35758533-67899CC6-1E47-4873-A232-50195DC745B5

Q35758533-67E7180A-6C10-41D9-8F56-DA771F9763E1

Q35758533-7A21600D-B996-4462-807D-56FEA1DEEA78

Q35758533-8B754577-2A12-4C74-93CA-30AC6C065F23

P304

Q35758533-8FE93B0B-1EEA-4D50-A0FC-BE05A180472C

P31

Q35758533-41FA0ADA-C7D4-4AAD-8088-228383A82F92

P356

Q35758533-923676E9-9DC5-46A8-9C08-F6B920D5393D

P433

Q35758533-046FDF00-60AE-40A8-904A-839F04287710

P478

Q35758533-DAB74F54-7853-4543-A129-3EA9F1E59D6A

P577

Q35758533-DABE9B3B-F912-402A-999E-247567E764E6

P698

Q35758533-316C443C-957B-4FC5-8AC5-80A165979139

P921

Q35758533-E1043442-6575-4772-A8BE-5B10BD488EA3

P932

Q35758533-E56D3252-1381-4A8F-A716-71509B4F27DB

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Glucocorticoids and relapse an ...... cytoplasmic antibody disease.

@en

P2093

Caroline E Jennette

http://www.w3.org/2001/XMLSchema#string

JulieAnne G McGregor

http://www.w3.org/2001/XMLSchema#string

Patrick H Nachman

http://www.w3.org/2001/XMLSchema#string

Ronald J Falk

http://www.w3.org/2001/XMLSchema#string

Susan L Hogan

http://www.w3.org/2001/XMLSchema#string

Yichun Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

ANCA disease: where is this field heading?

Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis

Cyclophosphamide therapy in Wegener's granulomatosis.

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

Adverse effects of therapy for ANCA-associated vasculitis.

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.

High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate.

Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse.

P304

240-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.05610611

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22134625

http://www.w3.org/2001/XMLSchema#string

P921

P932

3280023

http://www.w3.org/2001/XMLSchema#string